United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - peptostreptococcus anaerobius (unii: yqi5qwb9du) (peptostreptococcus anaerobius - unii:yqi5qwb9du) - peptostreptococcus anaerobius 19 [hp_x] in 1 ml - for temporary relief of symptoms related to peptostrep infection including nasal or sinus congestion, and earache.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to peptostrep infection including nasal or sinus congestion, and earache.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - peptostreptococcus anaerobius (unii: yqi5qwb9du) (peptostreptococcus anaerobius - unii:yqi5qwb9du) - peptostreptococcus anaerobius 19 [hp_x] in 1 ml - for the temporary relief of symptoms related to peptostrep infection including nasal or sinus congestion, earache, urinary tract infections, and chronic fatigue syndrome. for the temporary relief of symptoms related to peptostrep infection including nasal or sinus congestion, earache, urinary tract infections, and chronic fatigue syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - minocycline hydrochloride dihydrate, quantity: 53.985 mg (equivalent: minocycline, qty 50 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate; povidone; sorbitol; microcrystalline cellulose; stearic acid; magnesium stearate; titanium dioxide; hypromellose; sunset yellow fcf; quinoline yellow; light liquid paraffin; sodium lauryl sulfate - indications as at 12 november 2003 : minocycline may be used for the treatment of infections caused by any of the following organisms provided that they have been shown by bacteriological testing to be susceptible to minocycline: escherichia coli, enterobacter aerogenes, haemophilus influenzae, klebsiella and proteus. it may also be used in the treatment of infections due to streptococcus pyogenes (group a beta-haemolytic) and streptococcus faecalis but because a large proportion of these organisms are resistant to tetracyclines, minocycline should be used only if the orgaisms have been shown to be definitely sensitive. tetracyclines, including minocycline, are not the drugs of choice in the treatment of staphylococcal infections. minocycline may be considered for the treatment of such infections only if other suitable agents are not available and the organism has been shown to be sensitive to minocycline. minocycline may be used in the treatment of tetracycline-resistant acne.

Ireland - English - HPRA (Health Products Regulatory Authority)

ivowen limited - amoxicillin; clavulanic acid - powder for solution for injection/infusion - 1000/200 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

ivowen limited - amoxicillin; clavulanic acid - powder for solution for injection/infusion - 2000/200 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

ivowen limited - amoxicillin; clavulanic acid - powder for solution for injection/infusion - 500/100 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor

Canada - English - Health Canada

taro pharmaceuticals inc - fusidic acid (fusidic acid hemihydrate) - cream - 2% - fusidic acid (fusidic acid hemihydrate) 2%

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin, quantity: 500 mg; clavulanic acid, quantity: 125 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - augmentin tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology): urinary tract infections (uncomplicated and complicated); lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; skin and skin structure infections. appropriate culture and susceptibility studies should be performed to identify the causative organisms(s) and its (their) susceptibility to augmentin tablets. however, when there is reason to believe an infection may involve any of the b-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and b-lactamase producing organisms susceptible to augmentin tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - powder for oral suspension - clavulanic acid 125 mg amoxicillin 875 mg - antibacterials for systemic use

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - powder for oral suspension - clavulanic acid 125 mg amoxicillin 1000 mg - antibacterials for systemic use